A5072962250- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- PARP inhibition in cancer therapy
- Pancreatic and Hepatic Oncology Research
- Economic and Financial Impacts of Cancer
- Ovarian cancer diagnosis and treatment
- HER2/EGFR in Cancer Research
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Advanced Breast Cancer Therapies
- Urban Transport and Accessibility
- Radiomics and Machine Learning in Medical Imaging
- Hepatocellular Carcinoma Treatment and Prognosis
- Medical Imaging Techniques and Applications
- Health Systems, Economic Evaluations, Quality of Life
- Traffic and Road Safety
- Esophageal Cancer Research and Treatment
- Cancer therapeutics and mechanisms
- RNA modifications and cancer
AstraZeneca (United Kingdom)
2016-2025
Sarah Cannon
2024
Peking University Cancer Hospital
2024
Tennessee Oncology
2024
Zhengzhou University
2024
Peking University
2024
Henan Cancer Hospital
2024
NHS Lanarkshire
2021
University of the West of Scotland
2021
AstraZeneca (United States)
2019
Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer. The efficacy of osimertinib as compared platinum-based therapy plus pemetrexed such unknown.
The phase III PACIFIC trial compared durvalumab with placebo in patients unresectable, stage non-small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolidation was associated significant improvements the primary end points of overall survival (OS; stratified hazard ratio [HR], 0.68; 95% CI, 0.53 to 0.87; P = .00251) progression-free (PFS [blinded independent central review; RECIST v1.1]; HR, 0.52; 0.42 0.65; < .0001), manageable safety. We report updated,...
Purpose Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing ( EGFRm) and T790M resistance mutations. AURA (NCT01802632) a phase I/II clinical trial to determine the dose, safety, efficacy of osimertinib. This article reports results from II extension component. Patients Methods with EGFR-TKI–pretreated EGFRm- T790M-positive advanced non–small-cell lung cancer (NSCLC) received once-daily osimertinib 80...
Purpose The AURA study ( ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine clinical activity and safety osimertinib (an epidermal growth factor receptor [EGFR] –tyrosine kinase inhibitor selective for EGFR–tyrosine sensitizing [ EGFRm] EGFR T790M resistance mutations) as first-line treatment EGFR-mutated advanced non–small-cell lung cancer (NSCLC). Patients Methods Sixty with locally or metastatic EGFRm NSCLC received 80 160 mg once daily...
Targeting the programmed cell death protein 1 (PD-1)/programmed ligand (PD-L1) axis has demonstrated clinical benefit in recurrent/metastatic head and neck squamous carcinoma (R/M HNSCC). Combining immunotherapies targeting PD-L1 cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) shown evidence of additive activity several tumor types. This phase III study evaluated efficacy durvalumab (an anti-PD-L1 monoclonal antibody) or plus tremelimumab anti-CTLA-4 versus standard care (SoC) R/M HNSCC...
Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Perioperative regimens may combine benefits of both to long-term outcomes. Download a PDF the Research Summary. We randomly assigned NSCLC (stage II IIIB [N2 node stage] according eighth edition AJCC Cancer Staging Manual) receive platinum-based chemotherapy plus durvalumab placebo administered intravenously every 3 weeks for 4 cycles before surgery, followed by 12...
•Median OS with osimertinib was 26.8 months versus 22.5 platinum–pemetrexed (HR 0.87, 95% CI 0.67–1.12; P = 0.277).•The lack of a significant survival benefit could reflect high percentage (73%) to crossover.•Analysis adjusted for crossover showed an HR 0.54 (95% 0.18–1.60).•Among patients receiving subsequent anticancer therapy, platinum chemotherapy the most common after (65%).•Grade ≥3 (possibly treatment-related) adverse events were observed less frequently (9% 34% platinum–pemetrexed)....
In the phase III CASPIAN study, first-line durvalumab in combination with etoposide plus either cisplatin or carboplatin (EP) significantly improved overall survival (OS) versus EP alone extensive-stage small-cell lung cancer (ES-SCLC). Durvalumab tremelimumab numerically OS EP, but did not reach statistical significance. Here we report updated censored patients after median follow-up of >3 years.805 treatment-naïve ES-SCLC were randomized 1 : to EP. The two primary endpoints for and EP.As...
Abstract Background: Recent trials have demonstrated the clinical benefit of immunotherapy in either neoadjuvant or adjuvant resectable (R) NSCLC setting. AEGEAN (NCT03800134) is a randomized, double-blind, placebo (PBO)-controlled trial assessing durvalumab (D) + chemotherapy (CT) followed by surgery (Sx) and D patients (pts) with R-NSCLC. Methods: Adults treatment (Tx)-naïve R-NSCLC (stage II-IIIB[N2]; AJCC 8th ed) ECOG PS 0/1 were randomized (1:1) to receive 1500 mg PBO IV platinum-based...
Adjuvant therapy with durvalumab, or without tremelimumab, may have efficacy in patients limited-stage small-cell lung cancer who do not disease progression after standard concurrent platinum-based chemoradiotherapy.
LBA246 Background: FLOT was established as a perioperative therapy for GC/GEJC following the Phase 2/3 FLOT4 study conducted in Germany, with pCR rate of 16% (Al-Batran et al, Lancet Oncol 2016). The global MATTERHORN (NCT04592913) showed statistically significant improvement D + vs placebo (P) at first interim analysis (Janjigian ESMO Congress 2023). Subgroup analyses by region and country were completed to assess rates benefit across population. Methods: Participants (pts) resectable...
In Study 19, maintenance monotherapy with olaparib significantly prolonged progression-free survival vs placebo in patients platinum-sensitive, recurrent high-grade serous ovarian cancer. 19 was a randomised, placebo-controlled, Phase II trial enrolling 265 who had received at least two platinum-based chemotherapy regimens and were complete or partial response to their most recent regimen. Patients randomised (capsules; 400 mg bid) placebo. We present long-term safety final mature overall...
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selective for both EGFR-TKI-sensitizing and T790M (threonine-to-methionine substitution at codon 790)-resistance mutations. The authors present long-term follow-up data from preplanned, pooled analysis of phase 2 studies, the AZD9291 First Time in Patients Ascending Dose Study (AURA) extension trial (clincialtrials.gov identifier NCT01802632) AURA2 (NCT02094261).Patients with...
<h2>Abstract</h2><h3>Introduction</h3> Currently, the role of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as adjuvant therapy for early-stage non–small-cell lung cancer after complete surgical tumor resection remains under investigation. We present rationale and study design ADAURA (ClinicalTrials.gov identifier, NCT02511106) trial, a multicenter, double-blind, randomized, placebo-controlled study. <h3>Patients Methods</h3> Study entry will be limited to adults aged ≥...
For patients with resectable, early-stage non-small-cell lung cancer (NSCLC), surgery is the primary treatment; however, 5-year survival rates remain poor. Postoperative adjuvant platinum-doublet chemotherapy associated a statistically significant but modest improvement in of ∼5% at 5 years and widely accepted as standard care Stage II-III NSCLC. Neoadjuvant has been similar improvements overall to therapy this setting. Durvalumab, high-affinity PD-L1 inhibitor, become for unresectable, III...
NEPTUNE, a phase 3, open-label study, evaluated first-line durvalumab plus tremelimumab versus chemotherapy in metastatic NSCLC (mNSCLC).Eligible patients with EGFR and ALK wild-type mNSCLC were randomized (1:1) to (20 mg/kg every 4 weeks until progression) (1 for up four doses) or standard chemotherapy. Randomization was stratified by tumor programmed death-ligand 1 expression (≥25% <25%), histologic type, smoking history. The amended primary end point overall survival (OS) blood mutational...
In the CASPIAN trial, first-line durvalumab plus platinum-etoposide (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small cell lung cancer (ES-SCLC). We report exploratory analyses of outcomes by programmed death ligand-1 (PD-L1) expression and tissue tumor mutational burden (tTMB).